ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0241

Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0240

Gout: A Gateway to Chronic Opioid Use?

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0094

Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium

(0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 0550

Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0562

HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0167

Healthcare Resource Utilization Associated with Tumor-Induced Osteomalacia: Review of Patient Histories Prior to Entry in Clinical Trial UX023T-CL201

(0155–0175) Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 0200

Herpes Zoster Prevalence in Patients with Rheumatic Diseases

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0311

Heterogeneity and Natural History of Medial Fixed Joint Space Width in Healthy Knees Among Women and Men: Data from Three Large Cohort Studies

(0308–0324) Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 0385

Heterogeneity of the Joint Location Supports the Importance of Local Factors in Early RA Synovitis : Analysis of the ERA UCLouvain Brussels Cohort

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0382

Heterogeneity Within a “difficult to Treat” Rheumatoid Arthritis Patients Cohort: 36% May Have a More Benign Course and Have Distinct Characteristics at bDMARD or tsDMARD Initiation

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0216

High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0121

High Prevalence of Mental Health Disorders Among Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus

(0117–0144) Epidemiology & Public Health Poster I

9:00AM-11:00AM: Abstract Number: 0394

Higher Intakes of Red Meat Are Associated with an Increased Risk of Developing Seropositive but Not Seronegative Rheumatoid Arthritis – Results from a Nested Case-Control Study

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0484

Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study

(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

9:00AM-11:00AM: Abstract Number: 0496

Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis

(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.